Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITHIODOTE vs GILENYA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
FDA-approved for the treatment of acute cyanide poisoning,Off-label: May be used for cyanide poisoning due to smoke inhalation or certain chemical exposures
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.
0.5 mg orally once daily, with or without food
Terminal elimination half-life: 2.5–3 hours in adults with normal renal function; prolonged in renal impairment.
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Sodium nitrite is partially metabolized to nitric oxide and other metabolites; sodium thiosulfate is primarily excreted unchanged in urine, with minor metabolism by rhodanese in the liver and kidneys.
Primarily metabolized by CYP4F2, and to a lesser extent by CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Extensive first-pass metabolism via reversible stereoselective phosphorylation to active metabolite fingolimod-phosphate; also undergoes oxidative metabolism. Elimination half-life is approximately 6-9 days.
Primarily renal as unchanged drug and metabolites; biliary/fecal excretion minimal (<5%).
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Approximately 90% bound to albumin.
Fingolimod is approximately 99.7% bound to plasma proteins, primarily to albumin and lipoproteins (including α1-acid glycoprotein). The main active metabolite, fingolimod-phosphate, is also highly bound (>99%).
0.35 L/kg, indicating moderate tissue distribution.
The volume of distribution (Vd) is approximately 17 L/kg (range 7–30 L/kg), indicating extensive tissue distribution, especially into erythrocytes (about 20% of total drug in blood) and sequestration in central nervous system and lymphoid tissues.
Oral: 60–80% (first-pass metabolism); IV: 100%.
Oral bioavailability is approximately 93% (range 84–98%). Absorption is not significantly affected by food, but to reduce the risk of bradycardia and atrioventricular block, the first dose should be taken in the morning after a low-fat or fat-free meal.
No dose adjustment required for mild-moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), consider reducing sodium thiosulfate dose by 50% and monitoring serum thiocyanate levels.
No dose adjustment required for mild to severe renal impairment including dialysis; monitor patients with severe renal impairment for bradycardia at treatment initiation
No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-severe (Child-Pugh B/C), use with caution; consider reducing sodium nitrite dose by 50% due to increased methemoglobinemia risk.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A and B) but initiate with caution and monitor liver enzymes
Children: Sodium nitrite 0.15-0.33 m L/kg of 3% solution (4.5-10 mg/kg) IV push over 2 minutes, followed by sodium thiosulfate 1.65 m L/kg of 25% solution (412.5 mg/kg) IV push over 10 minutes. Repeat half doses if symptoms persist.
Approved for pediatric patients aged 10 years and older: for body weight ≤40 kg, 0.25 mg orally once daily; for body weight >40 kg, standard adult dose of 0.5 mg orally once daily
Geriatric patients: Use weight-based dosing (same as adult). Start with lower doses (e.g., sodium nitrite 5 mg/kg) due to increased risk of hypotension and methemoglobinemia. Monitor vital signs frequently.
No specific dose adjustment recommended; use with caution due to potential for decreased renal function and increased sensitivity to bradycardia, monitor heart rate and blood pressure
None
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for at least 6 hours, including hourly pulse and blood pressure measurement, and ECG before and after first dose. Risk of infections, including fatal cryptococcal infections and other opportunistic infections. Risk of macular edema, especially in patients with uveitis or diabetes mellitus. Risk of posterior reversible encephalopathy syndrome (PRES). Risk of cutaneous malignancies (basal cell carcinoma, melanoma, Merkel cell carcinoma). Risk of fetal harm; advise females of reproductive potential of potential risk and need for effective contraception.
May cause severe hypotension, especially in children,Risk of methemoglobinemia with excessive sodium nitrite,Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as hemolysis may occur,Monitor methemoglobin levels, blood pressure, and oxygen saturation during therapy,Sodium thiosulfate may cause hypocalcemia in high doses
Bradyarrhythmia: First-dose monitoring required; avoid in patients with sinoatrial block, sick sinus syndrome, second-degree or third-degree AV block unless pacemaker present.,Infections: Monitor for infections; consider suspending treatment if serious infection occurs. Vaccination against varicella zoster virus recommended before initiation.,Macular edema: Ophthalmologic evaluation before and 3-4 months after starting treatment; more frequent assessments in patients with diabetes or uveitis.,Respiratory effects: Dose-dependent decrease in forced expiratory volume and diffusion capacity; monitor pulmonary function if clinically indicated.,Elevated liver enzymes: Monitor liver enzymes before and during treatment; discontinue if significant liver injury occurs.,Fetal harm: Effective contraception required during and for 2 months after discontinuation.,Cutaneous malignancies: Baseline and routine dermatologic evaluations recommended.,Immune system effects: Avoid live attenuated vaccines during and for 2 months after treatment.,Posterior reversible encephalopathy syndrome (PRES): Evaluate rapidly if symptoms such as severe headache, altered mental status, visual disturbances, or seizures occur.,Increased blood pressure: Monitor blood pressure.,Reactivation of hepatitis B virus in carriers: Screen before initiation.,Tumor risk: Overall increased risk of malignancies, especially skin cancers and lymphomas.
Hypersensitivity to any component of the product,Children under 6 months of age (relative contraindication due to increased risk of hypotension and methemoglobinemia)
Hypersensitivity to fingolimod or any excipient,Recent myocardial infarction (within last 6 months),Unstable angina,Stroke or transient ischemic attack (within last 6 months),History of second-degree Mobitz type II or third-degree AV block, sick sinus syndrome, or sinoatrial block unless patient has an implanted pacemaker,Baseline QTc interval ≥500 msec,Treatment with Class Ia or Class III antiarrhythmics,Severe untreated sleep apnea,Concomitant use of pimozide
No known food interactions. Avoid alcohol as it may impair liver function and worsen acidosis.
No significant food interactions reported; take with or without food. Avoid grapefruit juice? No known interaction.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemoglobinemia and hemolytic anemia due to methylene blue component; avoid near term due to risk of neonatal methemoglobinemia.
FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at doses similar to human exposure). Second and third trimesters: limited human data; animal studies show reduced fetal weight and increased fetal mortality. Risk cannot be excluded; use only if benefit outweighs risk.
No human data; methylene blue is excreted in breast milk with an M/P ratio of approximately 0.7. Potential for infant methemoglobinemia; caution advised. Consider withholding breastfeeding for 4-6 hours after maternal dose.
Not recommended during breastfeeding. Fingolimod is excreted in animal milk; unknown if excreted in human milk. M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bradycardia, infections, and immunosuppression.
Standard dosing (1 mg/kg IV) used in pregnancy; consider lower dose (0.5-1 mg/kg) if severe anemia or G6PD deficiency. No routine dose adjustment, but monitor for maternal hypotension and fetal bradycardia.
No established dose adjustment in pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, decreased protein binding) may reduce exposure; consider therapeutic drug monitoring if available. Discontinue if pregnancy occurs unless benefit clearly outweighs risk.
NITHIODOTE (sodium nitrite and sodium thiosulfate) is indicated for acute cyanide poisoning. Administer intravenously as soon as possible after exposure. Monitor methemoglobin levels; do not exceed 20% methemoglobinemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Sodium nitrite induces methemoglobinemia which can impair oxygen delivery; ensure adequate ventilation. Sodium thiosulfate is generally safer and can be given separately.
GILENYA (fingolimod) requires first-dose monitoring for 6 hours due to risk of bradyarrhythmia; obtain baseline ECG, CBC, LFTs, and ophthalmologic exam. Avoid in patients with recent MI, unstable angina, stroke, or certain arrhythmias. Monitor for infections, especially cryptococcal meningitis and PML. Rebound disease activity may occur upon discontinuation. Lymphopenia is expected; monitor lymphocyte counts regularly.
This medication is only used in hospital settings for cyanide poisoning.,It is given through an IV line as soon as possible after exposure.,You may experience symptoms of low oxygen such as headache, confusion, or blue skin due to methemoglobin formation.,Tell your doctor if you have a history of G6PD deficiency, anemia, or breathing problems.,Follow-up blood tests will be needed to monitor your oxygen levels and blood counts.
Take exactly as prescribed; do not skip doses without consulting your doctor.,You will need a 6-hour observation period after the first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) or visual changes immediately.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 2 months after stopping, as it may harm a fetus.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITHIODOTE vs GILENYA, answered by our medical review team.
NITHIODOTE is a Cyanide Antidote that works by Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.. GILENYA is a Sphingosine 1-Phosphate Receptor Modulator that works by Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITHIODOTE and GILENYA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITHIODOTE is: NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.. The standard adult dose of GILENYA is: 0.5 mg orally once daily, with or without food. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITHIODOTE and GILENYA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITHIODOTE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemogl. GILENYA is classified as Category C. FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at do. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.